Here’s the latest on COVID-19 vaccines

In the first data available since authorized immunizations began in the U.S. in December, the CDC reports 353 adverse events. Roughly 1.9 million doses have been served nationwide.
Novavax has begun a phase three study of its COVID-19 vaccine in the U.S. and Mexico. The study will evaluate the vaccine’s safety and efficacy in up to 30,000 adults.
The European Union has launched its mass vaccination campaign with the Pfizer-BioNTech COVID-19 vaccine.